丁国鹏 1谢桂军 1张淼 1刘涛 2丁国龙 3雷姝4
作者信息
- 1. 721000 陕西宝鸡,宝鸡市人民医院
- 2. 721000 陕西宝鸡,宝鸡市中心医院
- 3. 710002 陕西西安,西安市第一医院
- 4. 721000 陕西宝鸡,宝鸡市妇幼保健院
- 折叠
摘要
Abstract
Objective To evaluate the therapeutic efficacy of tumor necrosis factor-α(TNF-α)antagonists in patients with ankylosing spondylitis(AS)-associated uveitis.Methods This was a multicenter retrospective case series study.A total of 87 patients with AS-associated uveitis who were treated in Baoji People's Hospital and Baoji Central Hospi-tal between December 2021 and December 2024 and had complete electronic medical records were included.Among them,75 were male and 12 were female,with a mean age of(30.7±13.2)years(range,16～52 years).Patients were divided into two groups according to whether they received TNF-α antagonist therapy.The control group included 43 patients who re-ceived conventional topical corticosteroid eye drops combined with nonsteroidal anti-inflammatory drugs(NSAIDs),while the study group included 44 patients who received TNF-α antagonists in addition to conventional treatment.Age,sex,and disease duration were collected.Aqueous humor cell count(AHCC),the best-corrected visual acuity(BCVA),Bath Ankylos-ing Spondylitis Disease Activity Index(BASDAI),and uveitis recurrence during the 12-month follow-up were compared be-tween the two groups before the treatment and at 1 week,3 weeks,2 months,3 months,6 months and 12 months after the treatment.Results There were no statistically significant differences in baseline characteristics between the two groups be-fore the treatment(all P＞0.05).At 1 and 3 weeks after the treatment,there were no statistically significant differences in AHCC,logMAR BCVA,or BASDAI between the two groups(all P＞0.05).At 2,3,6 and 12 months after the treatment,AHCC and BASDAI were lower in the study group than in the control group(all P＜0.05).At 3,6 and 12 months after the treatment,logMAR BCVA was lower in the study group than in the control group(all P＜0.05).During the 12-month follow-up,recurrence occurred in 20 patients in the control group,with a recurrence rate of 46.51％,and in 11 patients in the study group,with a recurrence rate of 25.00％.The difference between the two groups was statistically significant(P=0.036).Conclusions TNF-α antagonist therapy for AS-associated uveitis can reduce aqueous humor cell count,improve logMAR BCVA,lower the recurrence rate of uveitis,and reduce AS disease activity.It may represent an effective therapeu-tic strategy for patients with AS-associated uveitis.关键词
强直性脊柱炎/葡萄膜炎/非甾体抗炎药/肿瘤坏死因子拮抗剂Key words
Ankylosing spondylitis/Uveitis/Nonsteroidal anti-inflammatory drugs/Tumor necrosis factor-α an-tagonist
